I’m excited to leverage my experience as a medicinal chemist in the areas of heterobifunctional protein degradation, molecular glues, and covalent inhibition to help advance Entact’s goal of enhancing protein function through deubiquitination. Prior to Entact, I held positions of increasing responsibility at Ribon Therapeutics, Warp Drive Bio, and Ironwood Pharmaceuticals. I received my Ph.D. in organic chemistry from Columbia University in the field of asymmetric synthetic methodology and I conducted post-doctoral research at Memorial Sloan Kettering Cancer Center. Outside of work I love traveling with my family, collecting records, and long-distance running.
See what Nick and their colleagues have been up to:
ISGylation-independent protection of cell growth by USP18 following interferon stimulation
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Guiding a young, groundbreaking company to maturity calls for a leader who can strike the right balance between oversight and support. Victoria Richon is hoping to provide just that as the new CEO of Entact Bio, a preclinical biotech that came out of stealth in December...